Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study was to determine whether the acute ergogenic effects of caffeine differ according to the velocity metric used to assess strength performance against different relative loads. Thirteen resistance-trained men completed a triple-blind, randomized, placebo-controlled, crossover study. Participants ingested either caffeine (3 mg·kg-1) or a placebo 60 min before performing bench press and back squat exercises at 25%, 50%, 75%, and 90% of one-repetition maximum (1RM). Mean velocity (MV) and mean propulsive velocity (MPV) were simultaneously recorded using a linear position transducer
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Caffeine | Experimental | Acute caffeine intake (3 mg·kg-1) |
|
| Placebo | Placebo Comparator | Acute placebo intake (3 mg·kg-1 of maltodextrin) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Caffeine | Dietary Supplement | Acute caffeine intake (3 mg·kg-1) |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Velocity metrics against different relative loads of one-repetition maximum | Measuring bar mean velocity (during propulsive and braking phases in m/s) and mean propulsive velocity (m/s of the propulsive phase) displacement of the concentric phase during bench press and back squat exercises at 25%, 50%, 75%, and 90%1RM. | Through study completion, an average of 3 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse effects | perception of power, endurance, energy and exertion, as well as heart, muscular and gastrointestinal discomfort were measured using a 5-point scale, with scores ranging from 1 (lowest perception or absence of symptoms) to 5 (highest perception or severity). | Through study completion, an average of 3 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá | Alcalá de Henares | Madrid | 28805 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002110 | Caffeine |
| ID | Term |
|---|---|
| D014970 | Xanthines |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D011688 | Purinones |
Not provided
Not provided
Not provided
Not provided
Not provided
Statistician
| Placebo |
| Dietary Supplement |
Acute placebo intake (3 mg·kg-1 of maltodextrin) |
|
| D011687 |
| Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |